• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疾病与死亡的影响:负荷模型与质量调整生命年模型的比较

Impact of illness and death: comparison of Load and QALY models.

作者信息

Benson Tim

机构信息

R-Outcomes Ltd, Newbury, UK

Institute of Health Informatics, UCL, London, UK.

出版信息

BMJ Open Qual. 2025 Mar 18;14(1):e003190. doi: 10.1136/bmjoq-2024-003190.

DOI:10.1136/bmjoq-2024-003190
PMID:40102041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12551635/
Abstract

BACKGROUND

When allocating resources health decision-makers make trade-offs between different outcomes, such as morbidity and mortality. The Load and QALY (quality-adjusted life year) models are two approaches that have been developed to help value health and care outcomes.

METHODS

I briefly describe preference judgements, the Load and QALY models.

RESULTS

The same preference judgement, based on the standard gamble, is applied to a single hypothetical individual's lifetime, who dies at age 75 after 3 years of illness. In this example, the morbidity/mortality ratio using the Load model is 50 times higher than using the QALY model.

CONCLUSIONS

These findings, placing greater value on illness, call for further exploration, and in particular, whether the Load model can reshape healthcare policies and resource allocation.

摘要

背景

在分配资源时,卫生决策者会在不同结果之间进行权衡,如发病率和死亡率。负荷模型和质量调整生命年(QALY)模型是为帮助评估健康和护理结果的价值而开发的两种方法。

方法

我简要描述了偏好判断、负荷模型和QALY模型。

结果

基于标准博弈的相同偏好判断应用于一个假设个体的一生,该个体在患病3年后于75岁死亡。在此示例中,使用负荷模型得出的发病率/死亡率比使用QALY模型高出50倍。

结论

这些更重视疾病的发现需要进一步探索,特别是负荷模型是否能够重塑医疗保健政策和资源分配。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45c9/12551635/2c48d71e55fe/bmjoq-14-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45c9/12551635/2c48d71e55fe/bmjoq-14-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45c9/12551635/2c48d71e55fe/bmjoq-14-1-g001.jpg

相似文献

1
Impact of illness and death: comparison of Load and QALY models.疾病与死亡的影响:负荷模型与质量调整生命年模型的比较
BMJ Open Qual. 2025 Mar 18;14(1):e003190. doi: 10.1136/bmjoq-2024-003190.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Mid Forehead Brow Lift额中眉提升术
4
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
5
Vesicoureteral Reflux膀胱输尿管反流
6
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
7
Sexual Harassment and Prevention Training性骚扰与预防培训
8
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
9
Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research.妊娠期和产褥期的血栓预防:一项系统评价和经济评估,以估算未来研究的价值。
Health Technol Assess. 2024 Mar;28(9):1-176. doi: 10.3310/DFWT3873.
10
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗:一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.

引用本文的文献

1
Why EQ-5D and the Oxford Hip and Knee scores do not measure the same things.为什么EQ-5D量表与牛津髋关节和膝关节评分所衡量的内容不同。
BMJ Open Qual. 2025 Jun 8;14(2):e003214. doi: 10.1136/bmjoq-2024-003214.

本文引用的文献

1
Quality-Adjusted Life Years, Quality-Adjusted Life-Year-Like Measures, or Neither? The Debate Continues.质量调整生命年、类质量调整生命年指标,还是两者皆非?争论仍在继续。
Value Health. 2024 Jun;27(6):689-691. doi: 10.1016/j.jval.2024.04.021. Epub 2024 May 3.
2
The Value of the Quality-Adjusted Life Years.质量调整生命年的价值。
Value Health. 2024 Jun;27(6):702-705. doi: 10.1016/j.jval.2024.04.018. Epub 2024 May 2.
3
The QALY at 50: One story many voices.50岁时的质量调整生命年:众说纷纭的一个故事。
Soc Sci Med. 2022 Mar;296:114653. doi: 10.1016/j.socscimed.2021.114653. Epub 2021 Dec 11.
4
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.欧洲健康偏好研究:在药品营销许可、报销和定价决策中的应用综述——ISPOR 偏好研究特别兴趣小组报告。
Value Health. 2020 Jul;23(7):831-841. doi: 10.1016/j.jval.2019.11.009. Epub 2020 Jul 5.
5
Do the Benefits of COVID-19 Policies Exceed the Costs? Exploring Uncertainties in the Age-VSL Relationship.新冠疫情政策的收益是否超过成本?探究年龄-生命价值关系中的不确定性。
Risk Anal. 2021 May;41(5):761-770. doi: 10.1111/risa.13561. Epub 2020 Jul 16.
6
Valuing health-related quality of life: An EQ-5D-5L value set for England.重视与健康相关的生活质量:英国的EQ-5D-5L价值集。
Health Econ. 2018 Jan;27(1):7-22. doi: 10.1002/hec.3564. Epub 2017 Aug 22.
7
Health Preference Research: An Overview.健康偏好研究:概述
Patient. 2017 Aug;10(4):507-510. doi: 10.1007/s40271-017-0253-9.
8
The Load Model: an alternative to QALY.负荷模型:质量调整生命年的替代方法。
J Med Econ. 2017 Feb;20(2):107-113. doi: 10.1080/13696998.2016.1229198. Epub 2016 Sep 7.
9
Extending life for people with a terminal illness: a moral right and an expensive death? Exploring societal perspectives.延长绝症患者的生命:一项道德权利与代价高昂的死亡?探索社会观点。
BMC Med Ethics. 2015 Mar 7;16:14. doi: 10.1186/s12910-015-0008-x.
10
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.每获得一个质量调整生命年的增量成本?评估超罕见疾病医疗干预措施的替代方法的必要性。
J Comp Eff Res. 2014 Jul;3(4):399-422. doi: 10.2217/cer.14.34.